Do you want to visit this external website and leave amgenpro.com.au?
You are now leaving this Amgen Australia website. Amgen Australia assumes no responsibility for, and exercises no control over, the organizations, opinions, or accuracy of the information on the server or website you are redirected to.
Do you want to visit this external website and leave amgenpro.com.au?
You are now leaving this Amgen Australia website. Amgen Australia assumes no responsibility for, and exercises no control over, the organizations, opinions, or accuracy of the information on the server or website you are redirected to.
You can paste this link into an email or message to share this resource with your patient.
Overview Nplate® (romiplostim)
Nplate® (romiplostim)
Nplate® is indicated for treatment of thrombocytopenia in adult patients with primary immune thrombocytopenia (ITP) who are:
- non-splenectomised and have had an inadequate response, or are intolerant, to corticosteroids and immunoglobulins;
- splenectomised and have had an inadequate response to splenectomy.
Nplate® is indicated for treatment of thrombocytopenia in paediatric patients aged 1 year and older with primary immune thrombocytopenia ITP for at least 6 months who are:
- non-splenectomised and have had an insufficient response, or are intolerant, to corticosteroids and immunoglobulins;
- splenectomised and have had an inadequate response to splenectomy.
AmgenPro is intended for healthcare professionals in Australia
Login or create an AmgenPro account to access the latest updates on our products, medical resources and patient programs.
